Podiatrists in Elmhurst, NY Accepting Medicare
6 Podiatrists found. Showing 1 - 6
 Daniel D. Mathews Dpm Pc Podiatrist - Foot Surgery Medicare: Not Enrolled in Medicare Practice Location: 4035 95th St, Lower Level, Elmhurst, NY 11373 Phone: 718-205-6201 Fax: 718-205-5664 |
Elmhurst Podiatry Group Pc Podiatrist Medicare: Medicare Enrolled Practice Location: 8708 Justice Ave, Suite Cx, Elmhurst, NY 11373 Phone: 718-446-4230 Fax: 718-457-7015 |
Emmanuel Bustos Dpm Pc Podiatrist Medicare: Medicare Enrolled Practice Location: 4045 Elbertson St, Elmhurst, NY 11373 Phone: 718-916-0043 |
 Dr. Joaquin Diaz Jr., DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 87-08 Justice Ave, Suite Ck, Elmhurst, NY 11373 Phone: 718-899-0900 Fax: 718-899-8118 |
Dr. Collier Chan, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 8708 Justice Ave, Suite Cx, Elmhurst, NY 11373 Phone: 718-446-4230 Fax: 718-457-7015 |
Yuen Podiatry Pc Podiatrist - Foot & Ankle Surgery Medicare: Medicare Enrolled Practice Location: 8510 Queens Blvd, Elmhurst, NY 11373 Phone: 646-520-7027 Fax: 929-242-4312 |
News Archive
Not enough insurance and swimming in medical bills
As part of the series, "Are You Covered?" Kaiser Health News and NPR report that "more than 25 million Americans have Swiss-cheese health insurance: it's full of holes. Experts call them the 'under-insured'" (Knox, 9/28).
Alzheimer's disease: Gene expression level influences promotion of disorder or protection against development
Using sophisticated techniques that scan the genomes of patients, researchers at the Mayo Clinic campus in Florida have found that a gene appears to either help protect against development of Alzheimer's disease, or promote the disorder depending on the level of gene in the brain.
Prothelia, University of Nevada, Reno and Alexion partner to develop Laminin-111 for MDC1A
Prothelia Incorporated and University of Nevada, Reno announce that they have entered into strategic agreements with Alexion for the development of Laminin-111, a patented experimental protein replacement therapy for merosin-deficient congenital muscular dystrophy (MDC1A), a life-threatening, ultra-rare disease caused by a genetic deficiency of the Laminin-211 protein.
Nabi Biopharmaceuticals reports revenue of $4.8M for second-quarter 2010
Nabi Biopharmaceuticals today announced its second quarter financial results for the three month period ended June 26, 2010. The Company reported a net loss from continuing operations of $3.4 million, or $0.08 per share, compared to a net loss of $5.8 million, or $0.11 per share, for the period ended June 27, 2009.
› Verified 6 days ago
Physical Therapists
Speech-Language Pathologists
Occupational Therapists
Optometrists
Audiologists
Chiropractors
Podiatrists